References
- San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A pratical update on the use of bortezomib in the management of multiple myeloma. The Oncologist 2006; 11: 51–61
- Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665–7
- Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005; 25: 1820–5
- Grassinger J, Sudhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85: 132–3
- Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response in patients with multiple myeloma treated with high-dose therapy and hemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–23
- Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, et al. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288–94
- Jimenez-Zepeda VH, Dominguez VJ. Plasma cell leukemia: A rare condition. Ann Hematol 2006; 85: 263–7
- Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131: 71–3